Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CFD | P00746 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.38 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344790 | 0.98 | CYP3A4 (0.46) | CYP3A4LMNAHPGDHIF1AHSD17B10 | |
| SCHEMBL344635 | 0.98 | CYP3A4 (0.46) | CYP3A4LMNAHPGDHIF1AHSD17B10 | |
| SCHEMBL344789 | 0.83 | PTGS1 (0.54) | CYP3A4KMT2AALDH1A1TSHRGAA | |
| Potassium Ion SCHEMBL344634 | 0.83 | PTGS1 (0.50) | CYP3A4KMT2AALDH1A1TSHRGAA | |
| SCHEMBL29556983 | 0.83 | KMT2A (0.61) | CYP3A4LMNAKMT2AALDH1A1TSHR | |
| SCHEMBL343567 | 0.83 | KMT2A (0.61) | CYP3A4LMNAKMT2AALDH1A1TSHR | |
| SCHEMBL342726 | 0.81 | KMT2A (0.59) | CYP3A4LMNAKMT2AALDH1A1TSHR | |
| SCHEMBL28868246 | 0.79 | LMNA (0.47) | LMNAHPGDHIF1AHSD17B10KMT2A | |
| SCHEMBL12094224 | 0.77 | TSHR (0.60) | CYP3A4ALDH1A1TSHRGAAKDM4E | |
| SCHEMBL1889216 | 0.77 | LMNA (0.45) | LMNAHPGDHIF1AHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | claimed |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | claimed |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2018-02-01 | — | — | US | claimed |
| US-9511044-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2016-12-06 | — | — | US | claimed |
| US-9248114-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ | ACTION MEDICINES, S.L. (ES) | 2016-02-02 | — | — | US | claimed |
| US-9198886-B2 | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-12-01 | — | — | US | claimed |
| US-9060966-B2 | Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-06-23 | — | — | US | claimed |
| US-9018195-B2 | Use of 2,5-dihydroxybenzene sulfonic acid compounds for treating skin photoaging | AmDerma Pharmaceuticals, LLC (US) | 2015-04-28 | — | — | US | claimed |
| US-8889737-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2014-11-18 | — | — | US | claimed |
| US-20140328778-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | ACTION MEDICINES, S.L. (ES) | 2014-11-06 | — | — | US | claimed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020027-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020030-A1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020028-A1 | 2,5 DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF ROSACEA | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020040-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF FIBROSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020033-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020032-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | CYP3A4 163/4885LMNA 2915/4885HPGD 198/4885 |
| US-20140328778-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | CYP24A1, CYP8B1, CYP26B1 | CYP3A4 407/4885LMNA 3875/4885HPGD 116/4885 |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | CYP3A4 163/4885LMNA 2915/4885HPGD 198/4885 |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | ALDH1A2, IDH3A, IDH3B | CYP3A4 303/4885LMNA 2298/4885HPGD 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.